J&J beats earnings estimates; Middle East conflict weighs on medical device sales

2

By Michael Erman Oct 13 (Reuters) – Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of immune disease treatment Tremfya, but geopolitical issues

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)